NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
168 trialsNCT05327010 2026-03-18
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05554341 2026-03-18
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05554380 2026-03-18
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05638295 2026-03-17
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07477457 2026-03-17
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT01900743 2026-03-13
REGO-SARC
Centre Oscar Lambret
Phase 2 Completed
NCT04927416 2026-03-13
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05440786 2026-03-12
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting
NCT05755113 2026-03-12
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
QBiotics Group Limited
Phase 2 Recruiting
NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06933329 2026-03-10
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
BicycleTx Limited
Phase 2 Recruiting
NCT04829604 2026-03-09
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Ambrx, Inc.
Phase 2 Active not recruiting
NCT06311214 2026-03-06
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07450859 2026-03-05
A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
BicycleTx Limited
Phase 2 Recruiting
NCT03994796 2026-03-04
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Suspended
NCT05335941 2026-03-04
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01560416 2026-03-03
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04138628 2026-03-02
TOMBOLA
Aarhus University Hospital
Phase 2 Active not recruiting
NCT04771520 2026-03-02
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04606771 2026-02-27
CoC
AstraZeneca
Phase 2 Active not recruiting
NCT07282834 2026-02-27
Charlie-2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 2 Recruiting
NCT07432295 2026-02-25
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT04233567 2026-02-24
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT06630416 2026-02-24
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT07431073 2026-02-24
METAREM
UNICANCER
Phase 2 Not yet recruiting
NCT06005974 2026-02-23
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
Phase 2 Terminated
NCT06058988 2026-02-23
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07193394 2026-02-23
H3RAKLES
Institut Curie
Phase 2 Recruiting
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07424664 2026-02-20
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT05117931 2026-02-17
A Study of Amivantamab in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05853575 2026-02-17
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
Phase 2 Recruiting
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT06358677 2026-02-13
FACE
University of Utah
Phase 2 Recruiting
NCT07285993 2026-02-13
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT03993353 2026-02-12
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
Phase 2 Completed
NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT07405736 2026-02-12
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05726383 2026-02-10
Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
Hackensack Meridian Health
Phase 2 Recruiting
NCT07336238 2026-02-09
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
University of Washington
Phase 2 Not yet recruiting
NCT06778408 2026-02-05
HART
University of Vermont Medical Center
Phase 2 Recruiting
NCT07176312 2026-02-04
ZANGEA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06027268 2026-02-03
ToPCourT
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT06682806 2026-02-02
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 2 Terminated
NCT07183319 2026-02-02
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
Phase 2 Recruiting
NCT03964727 2026-01-30
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting